Skip to main content
OpenTrials

Clinical trial condition

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Explore clinical trials studying Metastatic Castration Resistant Prostate Cancer (mCRPC). Study availability and eligibility vary by location and protocol.

10 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC) trial results

Recruiting

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT03460977

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Disease Attributes, +23 more
Locations
  • Banner-University Medical Center Tucson Tucson, Arizona, United States
  • The University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • Arizona Urology Specialists, PLLC Tucson, Arizona, United States
View all 83 locations
View Trial Details
Recruiting

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

NCT07285694

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +12 more
Locations
  • City of Hope Duarte, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) Aurora, Colorado, United States
View Trial Details
Completed

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03480646

Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC), Neoplasms
Locations
  • Alaska Urological Institute Anchorage, Alaska, United States
  • Beverly Hills Cancer Center (BHCC) Beverly Hills, California, United States
  • John Wayne Cancer Inst. Duarte, California, United States
  • UCLA Los Angeles, California, United States
View all 41 locations
View Trial Details
Completed

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03724747

Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Locations
  • Tulane Medical Center New Orleans, Louisiana, United States
  • GU Research Network, LLC Omaha, Nebraska, United States
  • Memorial Sloan-Kettering Cancer Center New York, United States
  • HUS, Meilahden sairaala Helsinki, Finland
View Trial Details
Active, Not Recruiting

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

NCT06894511

Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Locations
  • Cancer And Blood Spclsts of AZ Casa Grande, Arizona, United States
  • Arizona Center for Cancer Care Gilbert, Arizona, United States
  • Hoag Memorial Hospital Presbyterian Newport Beach, California, United States
  • Cancer Specialists of North Florida Jacksonville, Florida, United States
View Trial Details

Related conditions